ATAI Life Sciences aims to transform mental health care, backing companies working on new treatments for depression, anxiety and addiction. Now, it’s adding digital tools to the mix through a new company called IntroSpect Digital Therapeutics.
ATAI adds MDMA biotech to growing list of psychedelic makers; Acadia adds $52.5M upfront pain buyout
atai Life Sciences launches InnarisBio, in partnership with the University of Queensland, with the aim to develop a more effective nose-to-brain delivery method for atai’s platform of mental health therapeutic programs
BERLIN and BRISBANE, Australia, July 28, 2021 (GLOBE NEWSWIRE) — atai Life Sciences (“atai” or the “Company”) (Nasdaq: ATAI), a clinical-stage biopharmaceutical company…
JOIN THE ATAI #INSIGHTNETWORK